OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
XBIO
Xenetic Biosciences, Inc.
There isn't enough reported data to score XBIO yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
XBIO Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Unavailable |
XBIO's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
XBIO PE Valuation
XBIO has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
XBIO Forward outlook
There aren't enough analyst estimates for XBIO to show an outlook.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over XBIO on earnings quality, reporting a profit while its opponent remains loss making.
XBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.54 | +$0.51 |
| Q2 2026 | -$1.15 | +$0.85 |
| Q1 2026 | -$1.19 | +$1.19 |
| Q4 2025 | -$1.58 | +$0.99 |
| Q3 2025 | -$2.05 | +$0.57 |
| Q2 2025 | -$2.00 | +$1.03 |
| Q1 2025 | -$2.38 | +$0.51 |
| Q4 2024 | -$2.57 | +$0.14 |
XBIO is still losing money, but far less than before: $1.54 per share over the past year, against $17.00 at its worst in late 2020.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over XBIO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over XBIO on profitability, with a higher operating margin.
XBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $725.3K | -29% |
| Q2 2026 | $660.6K | +12% |
| Q1 2026 | $806.9K | +36% |
| Q4 2025 | $766.3K | +18% |
| Q3 2025 | $1M | +67% |
| Q2 2025 | $589.9K | -19% |
| Q1 2025 | $593.3K | +16% |
| Q4 2024 | $648.8K | -3.4% |
XBIO's revenue fell from its 2025 peak and has held roughly level since: $725,257 last quarter, down 29% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -240% | -187 points |
| Q2 2026 | -147% | -24 points |
| Q1 2026 | -62% | +97 points |
| Q4 2025 | -81% | +88 points |
| Q3 2025 | -53% | +28 points |
| Q2 2025 | -123% | +61 points |
| Q1 2025 | -159% | +90 points |
| Q4 2024 | -169% | +18 points |
XBIO's operating margin was −240% last quarter, down 187 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over XBIO on cash generation, producing positive trailing cash flow while its opponent burns cash.
XBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$662.1K | -$3.9K |
| Q2 2026 | -$875.5K | -$491.7K |
| Q1 2026 | -$536.4K | +$465.5K |
| Q4 2025 | -$242.7K | +$431.3K |
| Q3 2025 | -$658.2K | -$199.2K |
| Q2 2025 | -$383.8K | +$141.3K |
| Q1 2025 | -$1M | +$157.5K |
| Q4 2024 | -$674K | +$119K |
XBIO has burned cash in almost every quarter: −$2M over the past year, against −$3M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over XBIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
XBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.1% | +48.8K shares |
| 1 year | +52% | +801K shares |
| 3 years | +54% | +818K shares |
| 5 years | +168% | +1.5M shares |
| Available history | +276% | +1.7M shares |
XBIO has 2M diluted shares, up 52% from a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
XBIO Net Leverage
XBIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
XBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.5 | Neutral |
| Stochastic | 8.3 | Oversold |
XBIO's weekly RSI is 37 (neutral) and its Stochastic is 8 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
XBIO PE vs Healthcare Sector
XBIO has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over XBIO on trend strength, trading above more of its moving averages.
XBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.01 | 17% below |
| 20 week MA | $2.74 | 39% below |
| 50 week MA | $2.72 | 39% below |
| 100 week MA | $3.06 | 46% below |
| 200 week MA | $3.54 | 53% below |
XBIO is in a downtrend: it's below all five of its weekly moving averages, and 53% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over XBIO on returns for 2026, with the stronger performance.
XBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.3 | $21.9 | +53% |
| 2021 | $21.9 | $14.4 | -34% |
| 2022 | $14.4 | $3.10 | -78% |
| 2023 | $3.10 | $3.45 | +11% |
| 2024 | $3.45 | $4.11 | +19% |
| 2025 | $4.11 | $2.08 | -49% |
| 2026 YTD | $2.08 | $1.66 | -20% |
XBIO has finished lower in three of the last six years. It's down 20% so far in 2026.